

RHINOMED STATEMENT PURSUANT TO LISTING RULE 4.7C

17 August, 2020: Melbourne, Australia.

Rhinomed Limited (ASX:RNO OTCQB:RHNMF) advises the following, pursuant to Listing Rule 4.7C, which came into effect for the quarter ended 31 March 2020:

In accordance with Listing Rule 4.7C.3, and as noted in Item 6 of the Appendix 4C Cash Flow Statement lodged by the Company with the Australian Securities Exchange (ASX) on 22 July 2020:

Item 6.1: Directors fees and salaries, excluding GST where applicable.

- Executive Board remuneration - \$81k
- Non-Executive Board remuneration - \$70k
- Amount shown at Item 6.1 includes an amount of \$33k for consulting fees paid to Smart Street Solutions, a related party of Michael Johnson.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.